Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab

NCT01783756 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT01783756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01783756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
June 26, 2013
Completion date
May 10, 2019
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system metastases, her2-positive breast cancer, male breast cancer, recurrent breast cancer, stage iv breast cancer